The little Samuel of casting suffers in his birth of the hereditary disease spinal muscular atrophy (SMA), which means that his muscles are not developed properly, reports the “Rheinische Post”. After he was first treated with the other possible, and cheaper drug Spinraza successfully, have deteriorated dramatically. For this reason, had been decided on Zolgensma switch.
“Significant improvement” at the Samuel
About a hardship program, the manufacturer Novartis put the drug in March available for free. Samuel had received a single Infusion of the Präperats, the life-long work. Today, almost four months later, it has to go to the little boy much better.
More to Zolgensma you can read here…
According to a spokesperson for the University hospital, be casting he and his parents “totally happy”. “With Samuel, we see the gift of Zolgensma a significant improvement in the course of the disease,” says the Director of the Giessen centre for rare diseases, Bernd Neubauer. He had become “more stable overall” and could now breathe at times independently.
Controversial Superiority of Zolgensma
Only a few days ago, another family had failed in court, as they called for a therapy with Zolgensma for their ill daughter, who refused to accept the health insurance, however. Was this on the basis that the child, the previous treatment with Spinraza be successful, and that, due to the incomplete Studies, the superior efficacy of Zolgensma is still controversial.
This also Bernd Neubauer affirms: “Which of the two drugs works better, one can’t generalize. We have also seen with Spinraza treatment success, which made us wonder. This depends for sure also very individually by the patient.“
3 No-Gos, the damage to your heart: you should not FOCUS Online 3 No-Gos, the damage to your heart to do: you should not
kas/dpa to do
